Literature DB >> 8386022

Genotypic subtyping of hepatitis C virus.

K Chayama1, A Tsubota, Y Arase, S Saitoh, I Koida, K Ikeda, T Matsumoto, M Kobayashi, S Iwasaki, S Koyama.   

Abstract

Four subtypes of hepatitis C virus (HCV), Pt(I), K1(II), K2a(III) and K2b(IV), have been suggested based on the nucleotide sequences of the non-structural (NS) 5 region. A fifth subtype from Japanese patients, Tr(V), which shows a less than 68% homology in nucleotide sequence when compared with other subtypes has been identified. A one-step method which enables a quick determination of subtype using polymerase chain reaction with a mixed primer set deduced from the sequence of each subtype has been developed. Using this technique, the subtypes of 418 out of 478 Japanese patients (87.4%) were determined. The incidence of each subtype in Japan was as follows: K1(II), 307 (73.4%); K2a(III), 74 (17.7%); K2b(IV), 28 (6.7%); and Tr(V), 3 (0.7%). This one-step subtyping technique should be useful for studying the epidemiology or biology of the HCV.

Entities:  

Mesh:

Year:  1993        PMID: 8386022     DOI: 10.1111/j.1440-1746.1993.tb01507.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  28 in total

1.  Management of chronic hepatitis C and prevention of hepatocellular carcinoma.

Authors:  Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

2.  Recent advances in laboratory diagnosis of hepatitis C virus infection.

Authors:  R Chaudhary
Journal:  Can J Infect Dis       Date:  1994-11

3.  Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes.

Authors:  L Stuyver; W van Arnhem; A Wyseur; F Hernandez; E Delaporte; G Maertens
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

4.  Subtyping of hepatitis C virus isolates by a line probe assay using hybridization.

Authors:  A Andonov; R K Chaudhary
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

Review 5.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a.

Authors:  O Ohno; M Mizokami; R R Wu; M G Saleh; K Ohba; E Orito; M Mukaide; R Williams; J Y Lau
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients.

Authors:  X Forns; M D Maluenda; F X López-Labrador; S Ampurdanès; E Olmedo; J Costa; P Simmonds; J M Sánchez-Tapias; M T Jimenez De Anta; J Rodés
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

8.  Relationship between pretreatment viremia level and response to interferon-alpha therapy in chronic hepatitis C differs in viral type 1 and 2 infections.

Authors:  A Tsubota; H Kumada; K Chayama; Y Arase; S Saitoh; I Koida; N Murashima; Y Suzuki; M Kobayashi; K Takagi; M Kobayashi; K Ikeda
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 9.  Recent advances in hepatitis C virus research.

Authors:  M Omata; N Kato
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

10.  Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection.

Authors:  Norio Akuta; Fumitaka Suzuki; Mariko Kobayashi; Akihito Tsubota; Yoshiyuki Suzuki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.